The 15th International Symposium on Translational Research in Oncology
Schedule
Wed Sep 28 2022 at 01:30 pm to Fri Sep 30 2022 at 05:00 pm
Location
Herbert Park Hotel and Park Residence | Dublin 4, DN
About this Event
15th International Symposium on Translational Research in Oncology
DRAFT PROGRAMME
Wednesday, 28th September 2022, Lansdowne Suite
09.00 - 12.30 AICRI Showcase To register for the AICRI showcase click here
Registration for symposium from 12:30 CPD: TBC external points
13:30 – 13.45 Welcome and Introduction – Prof John Crown, St. Vincent’s University Hospital, Dublin
TARGETED THERAPIES IN CANCER I: Session Chair – Prof. Sara Hurvitz, UCLA
13:45 – 14:15 Topic: Breast cancer overview
Prof. Sara Hurvitz, Professor of Medicine and Director, Breast Cancer Clinical Trials Program, Division of Hematology/Oncology, David Geffen School of Medicine, UCLA. Medical Director, Clinical Research Unit, Jonsson Comprehensive Cancer Center.
14:15 – 14:45 Therapeutic application of ADCs: challenging the current breast cancer classification
Dr. Aditya Bardia, Director, Breast Cancer Research, Medical Oncology, Massachusetts General Hospital Cancer Center, Associate Professor, Harvard Medical School, Boston
14:45 – 15:15 Beyond ADCs - Next Generation Targeted Therapeutics
Dr. Richard Markus, President and CEO, Dantari
15:15 – 15:30 Coffee break
TARGETED THERAPIES IN CANCER II: Session Chair – Prof. Sara Hurvitz, UCLA
15:30 - 16:00 Topic: Efforts to target claudin-family proteins with ADC in ovarian, gastric and pancreas cancer
Dr. Neil O'Brien, Adjunct Associate Professor, Dept of Medicine, Division of Hematology/Oncology, UCLA
16:00 - 16:30 Hepatobiliary Cancers: Clinical/ Scientific Advances and Unmet Needs
Dr. Richard Finn, Professor of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, UCLA.
KEYNOTE PRESENTATION
16:30 - 17:15 Keynote Topic: HER2 stories in breast cancer
Dr. Dennis J. Slamon, Director of Clinical/Translational Research, Director of the Revlon/UCLA Women's Cancer Research Program at JCCC. Professor of Medicine, Chief, Division of Hematology/Oncology and Executive Vice Chair for Research, Department of Medicine, UCLA.
_________________________________________________
Thursday, 29th September 2022, Lansdowne Suite, Herbert Park Hotel
Registration from 08:30 CPD: TBC external points
TUMOUR MICRO-ENVIRONMENT I: Session Chair – Prof. Bob Kerbel
09:00 - 09:30 Preclinical modelling of ‘authentic’ acquired resistance to immune checkpoint antibody blockade
Professor Bob Kerbel & Dr. Kabir Khan, University of Toronto
09:30 - 10:00 Effects of arenavirus-based immuno-virotherapy on the tumor microenvironment (TME): inducing tumor-destroying immune effects
Dr. Thomas Bogenrieder, CEO Amal Therapeutics
10:00 - 10:30 Clinical development of Olinvacimab and PMC-403 and their scientific rationale
Dr. Jin-San Yoo, President & CEO, PharmAbcine, Inc
10:30 - 10:45 Coffee break
TUMOUR MICRO-ENVIRONMENT II: Session Chair – Prof. Bob Kerbel
10:45 - 11:15 The immunological host response to immunotherapy: Towards biomarker discovery and therapeutic opportunities.
Prof Yuval Shaked, The Annie Chutick Chair in Medicine, Director, Rappaport-Technion-Integrated Cancer Center, Department of Cell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion - Israel Institute of Technology
11.15 – 11:45 Targeting the metastatic niche
Prof Janine Erler, Professor in Cancer Biology, Biotech Research and Innovation Centre, University of Copenhagen, Denmark
11:45 – 12:15 Stromal fibroblasts sculpt tumour evolution and therapy responses
Dr. Erik Sahai, Principal Group Leader, Assistant Research Director, The Francis Crick Institute, London
KEYNOTE PRESENTATION
12:15 – 13:00 Development of novel – ubiquitin system-based – anti cancer drugs.
Prof. Aaron Ciechanover, 2004 Nobel Laureate, Distinguished Professor, Technion-Israel Institute of Technology
13:00 - 14:00 Lunch
TARGETING DIFFICULT TO DRUG GENES FOR CANCER THERAPY
Session Chair – Prof Michael J. Duffy, St. Vincent’s University Hospital/University College Dublin
14:00 - 14:30 Targeting "Undruggable" Genes: Update 2022
Prof Michael J. Duffy, Clinical Research Centre, St. Vincent’s University Hospital, Dublin.
14:30 – 15:00 Developing a clinically viable MYC inhibitor for cancer treatment
Prof Laura Soucek, Group Leader, Vall d'Hebron Institut d'Oncologia, ICREA Research Professor, Spain
15:00 - 15:30 Sotorasib, the first approved KRAS inhibitor
John Waldron, Medical Science Liaison (Haematology/Oncology), Amgen Ireland
15:30 - 15:45 Coffee break
IO THERAPIES : Session Chair – Prof John Crown, St. Vincent’s University Hospital
15:45 - 16.15 The Evolution of Neoadjuvant Immunotherapy for Lung Cancer - Translational Science to Clinical Results
Dr. Patrick Forde, Assoc Prof Oncology, Johns Hopkins University, Baltimore
16:15 - 16:45 Title: TBC
Dr. Roisin O’Cearbhaill, Director, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Centre
16:45 - 17:15 Anti-CD47 plus trastuzumab induces macrophage phagocytosis (ADCP) of HER2-positive breast cancer cells selected for tolerance to trastuzumab-mediated ADCC.
Dr. Mark Pegram, Susy Yuan-Huey Hung Professor of Medical Oncology, Stanford University School of Medicine
_________________________________________
Friday 30th September 2022, Lansdowne Suite, Herbert Park Hotel
Registration from 8:30 CPD: TBC external points
NOVEL TARGETED DRUGS AND BIOMARKERS: Session Chair - Prof John Crown
09:00 - 09:30 Mapping the degradation landscape in cancer reveals insight into anti-tumor immunity
Dr. Yifat Merbl, Senior Scientist, Weizmann Institute of Science, Israel
09:30 - 10:00 Targeting Acetyl-CoA-carboxylase in breast cancer
Dr. Lajos Pusztai, Professor of Medicine at Yale University and Director of Breast Cancer Translational Research and Co-Director of the Cancer Center Genomics, Genetics, and Epigenetics Program
10:00 - 10:30 Using the immune system to detect cancer
Prof. Josh LaBaer, Executive Director, Biodesign Institute, Arizona State University
10:30 – 10:45 Coffee break
ANTIBODY DRUG CONJUGATES: Session Chair - Prof John Crown
10:45-11:15 Title: TBC
Dr. See Phan, VP, Clinical Research Oncology, Gilead Sciences
11:15 – 11:45 Topic: Development of Antibody-Drug-Conjugates
Dr. Rodney Smith, Head of European Medical Affairs Oncology, Daiichi-Sankyo
11:45 - 12:15 Title: TBC
Dr. Christopher Carosino, Associate Director Toxicology, Seagen
12:15 – 13:15 Lunch
CANCER IMMUNOTHERAPY I: Session Chair – Prof. Mario Sznol
13:15 - 13:45 The Future of Immunotherapy in Melanoma: LAG-3 and Beyond
Dr. Giuseppe Gullo, Sr. Director, Clinical Sciences, Oncology, Regeneron
13:45 - 14:15 Bench to bedside trials in uveal melanoma at Sylvester Cancer Center
Dr. Jose Lutzky, Leader, Cutaneous and Ocular Oncology Site Disease Group
Medical Director, Clinical Trials Office, Professor of Clinical Medicine, University of Miami Sylvester Comprehensive Cancer Center.
14:15 - 14:45 Title: TBC
Immunocore
14:45 – 15:00 Coffee break
CANCER IMMUNOTHERAPY II: Session Chair – Prof. Mario Sznol
15:00 – 15:30 Results of a RCT phase 3, comparing ipilimumab with TIL therapy for advanced stage melanoma having failed anti-PD-1
Prof. Dr. John. B.A.G. Haanen, Medical Oncology Department, Netherlands Cancer Institute
15:30 – 16:00 Designing and delivering next-generation TCR T-cell therapies
Dr. Elliot Norry, Chief Medical Officer, Adaptimmune LLC
16:00 – 16:30 Clinical validation of conceptually novel anti-hypoxia A2-adenosinergic immunotherapies in cancer patients who were otherwise refractory to all other current treatments
Prof Michail Sitkovsky, E.Black Professor of Immunophysiology and Pharmaceutical Biotechnology, Director, NE Inflammation and Tissue Protection Institute Northeastern University.
Meeting Ends
Where is it happening?
Herbert Park Hotel and Park Residence, Ballsbridge, Dublin 4, IrelandEUR 0.00